What would you use as next line of treatment for a patient with ROS1+ metastatic NSCLC progressing on first line TKI?  

If starting with entrectinib would you still try crizotinib, or move to lorlatinib or another novel TKI? Or change entirely to chemotherapy, immunotherapy or chemoimmunonotherapy?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution